Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00045968Phase 3Unknown

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Role: lead

NCT03014804Phase 2Withdrawn

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Role: collaborator

NCT03638765Phase 1Unknown

Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer

Role: lead

NCT00603460Phase 1Withdrawn

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

Role: collaborator

NCT02146066Unknown

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221

Role: lead

NCT01882946Phase 1Unknown

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Role: lead

NCT00043212Phase 3Withdrawn

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Role: lead

NCT00683241Phase 1Completed

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

Role: collaborator

All 8 trials loaded